MedTrace Logo

An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516

NCT00892944 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2009-10-28

No results posted yet for this study

Summary

The purpose of this study is to determine if AZD2516 binds to mGluR5 receptors in the brain. This will then help to make accurate predictions of efficacy and dosing in the future development programme.

Conditions

  • Healthy

Interventions

DRUG

AZD2516

Fractionated single oral dose

Sponsors & Collaborators

Principal Investigators

  • Ingemar Bylesjo, MD, PhD · AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden

  • Michael O'Malley · AstraZeneca R&D, Södertälje, Sweden

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Completion
2009-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892944 on ClinicalTrials.gov